ViewRay Announces Conference Call for First Quarter 2022 Financial Results to be Held After Market on May 5, 2022
ViewRay, Inc. (Nasdaq: VRAY) announced a conference call scheduled for May 5, 2022, at 4:30 p.m. ET to discuss its first-quarter financial results. The call can be accessed domestically at (844) 277-1426 and internationally at (336) 525-7129. A live webcast will be available on the company's investor relations site and will remain accessible for 14 days after the event. ViewRay specializes in innovative MR-guided radiation therapy systems, focusing on advanced radiation oncology.
- Scheduled conference call to review first-quarter 2022 financial results.
- MRIdian system addresses specific challenges in radiation oncology.
- None.
CLEVELAND, April 21, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its first quarter 2022 financial results.
ViewRay will hold a conference call to discuss results on Thursday, May 5, 2022 at 4:30 p.m. ET. The dial-in numbers are (844) 277-1426 for domestic callers and (336) 525-7129 for international callers. The confirmation number is 6274157. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at http://investors.viewray.com/events-and-presentations/upcoming-events.
After the live webcast, a replay will remain available online on the investor relations page of ViewRay's website, under "Financial Events and Webinars", for 14 days following the call. In addition, a telephonic replay of the call will be available until May 12, 2022. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the conference ID number 6274157.
About ViewRay®
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® MR-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
View original content:https://www.prnewswire.com/news-releases/viewray-announces-conference-call-for-first-quarter-2022-financial-results-to-be-held-after-market-on-may-5-2022-301529994.html
SOURCE ViewRay, Inc.
FAQ
When will ViewRay announce its first quarter 2022 financial results?
How can I listen to ViewRay's conference call for Q1 2022?
Where can I find the webcast of ViewRay's conference call?
What is the ticker symbol for ViewRay?
